Literature DB >> 6610384

Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.

D E Kuhl, E J Metter, W H Riege.   

Abstract

[18F]Fluorodeoxyglucose scans were performed on 9 patients with Parkinson's disease and 14 normal subjects. Five patients were restudied after an interval of 3 to 4 years. We found no selective metabolic change in striatum, where dopamine deficit is known to be greatest, in affected patients; cerebral glucose metabolism was reduced uniformly throughout the parkinsonian brain (average 18% decrease). With increased severity of bradykinesia and the development of mild to moderate dementia, global brain metabolism in Parkinson's disease decreased further. In one moderately demented patient with Parkinson's disease, severe parietal cortex hypometabolism was found, similar to that seen in Alzheimer's disease. In contrast, mildly to moderately demented patients with Huntington's disease have marked caudate hypometabolism, but cerebral glucose metabolism is normal elsewhere. It appears that in addition to the well-known neurotransmitter loss in the nigrostriatal system, there is an abnormal metabolic process involving neurons throughout the parkinsonian brain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610384     DOI: 10.1002/ana.410150504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

Review 1.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Simultaneous voltammetric detection of glucose and lactate fluctuations in rat striatum evoked by electrical stimulation of the midbrain.

Authors:  Alexandra G Forderhase; Hannah C Styers; Christie A Lee; Leslie A Sombers
Journal:  Anal Bioanal Chem       Date:  2020-07-14       Impact factor: 4.142

3.  [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.

Authors:  S Breit; M Reimold; G Reischl; T Klockgether; U Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  PET studies of cerebral metabolism in Parkinson disease.

Authors:  William J Powers
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

5.  6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys.

Authors:  D J Doudet; H Miyake; R T Finn; C A McLellan; T G Aigner; R Q Wan; H R Adams; R M Cohen
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

6.  Regional, kinetic [(18)F]FDG PET imaging of a unilateral Parkinsonian animal model.

Authors:  Matthew D Silva; Charles Glaus; Jacob Y Hesterman; Jack Hoppin; Geraldine Hill Della Puppa; Timothy Kazules; Kelly M Orcutt; Mary Germino; David Immke; Silke Miller
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

7.  Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities.

Authors:  N L Foster; S Gilman; S Berent; A A Sima; C D'Amato; R A Koeppe; S P Hicks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

8.  (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type.

Authors:  U Spampinato; M O Habert; J L Mas; M C Bourdel; M Ziegler; J de Recondo; S Askienazy; P Rondot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

9.  Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.

Authors:  M B Schapiro; P Pietrini; C L Grady; M J Ball; C DeCarli; A Kumar; J A Kaye; J V Haxby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

10.  Cerebral mitochondrial metabolism in early Parkinson's disease.

Authors:  William J Powers; Tom O Videen; Joanne Markham; Kevin J Black; Nima Golchin; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2008-06-25       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.